Additional file 5: Fig. S5 Dynamic changes in ctDNA concentration and radiographic tumor responses.

Additional file 6: Fig. S6 Concordance of ctDNA response and radiographic response.

Additional file 7: Fig. S7 Mutational profiles of CSF and plasma samples at baseline.

Additional file 8: Fig. S8 The proportion of clonal and subclonal mutations in CSF and plasma samples at baseline and after 8 weeks of treatment.

Additional file 1: Supplementary Figure 1. The original and uncropped gel image of AAT1.

Additional file 6: Figure S2. (A, F, K) Comparison of the relationship between the clinical characteristics of patients between high- and low-risk groups in the training, testing, and entire sets, respectively. (B–E) The scatter diagram showed the relationship between gender (B), clinical stage (C), T stage (D), N stage (E) and the risk score in the training set. (G–J) The scatter diagram showed the relationship between gender (G), clinical stage (E), T stage (F), N...

Supplementary Material 2

Supplementary Material 2

Supplementary Material 2

Additional file 1: Fig. S1. Sample size was estimated in advance using Gpower software.

MSHF: A Multi-Source Heterogeneous Fundus (MSHF) Dataset for Image Quality Assessment

Additional file 6: Fig. S3. Different from TTC12 expression that restricted to spermatocytes and respiratory ciliated cells (upper), TTC21B was universally expressed in most of tissues but possess relative lower expression levels in spermatocytes and respiratory ciliated cells (bottom) according to Human Protein Atlas Database ( www.proteinatlas.org )

Supplementary Material 2

Additional file 3: Fig. S2. Exome-based copy number alteration detection was performed followed by MLPA confirmation. (A-B) CNV analysis identified 16p13.11 microduplication (chr16: 14.82-15.12, 300kb) in the F1-II-1 (607P) but not in F1-II-2 (607S). The individual 692F served as a control. (C) MLPA confirmation of the gain of copy in PDXDC1, located in the 16p13.11 region, that identified from CNV analysis in the 607-P when compared with 607-S. Three independent probes were designed for each...

Additional file 2: Fig. S2. Methylation status of differentially methylated sites. (A-B) Volcano plots showing DMCs in the context of CHG (A) and CHH (B). (C) Bar plots showing distribution of differences in methylation levels of DMCs.

Additional file 7: Fig. S3. The original immunoblot images of HSP90. In order to save antibody and chromogenic reagent, the membranes were cut into strips just between the 70 KDa and 100 KDa molecular weight markers after transfer to a PVDF membrane and used for HSP90 immunoblot.

Additional file 8: Fig. S4. The original immunoblot images of LOX2. In order to save antibody and chromogenic reagent, the membranes were cut into strips just 1 cm above and below the 70 KDa molecular weight marker after transfer to a PVDF membrane and used for LOX2 immunoblot.

Additional file 3: Fig. S2. Multicollinearity analysis for BMI and the MNA-SF.

The alkaloids of Narcissus tazetta L. var. Chinensis Roem (Amaryllidaceae) have antitumor and antiviral activities. However, the immunopharmacological effects of one of its constituents, pseudolycorine chloride (PLY), have not been reported yet. We evaluated the effect of PLY on myeloid-derived suppressor cells (MDSCs) expansion and differentiation into monocyte-like MDSCs (M-MDSCs) and examined whether PLY alleviates Th17 cell-mediated experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). In vitro, MDSCs were treated with PLY...

Supplementary Material 11

Supplementary Material 2

Additional file 1. Fig. S1: Low doses of SI-2 exhibit better tumor-suppressive activity than high doses of SI-2. A Reduction in luciferase activity in E0771 tumors in B6 albino mice by SI-2 (2.5 mg/kg and 5 mg/kg) treatment compared with vehicle treatment. Quantification of luciferase activity in the E0771 breast tumors shown in Panel A. B–D. Numbers of CD4+ T cells (B), CD8+ T cells (C), and CD56+ NK cells (D) in E0771 breast tumors...

Additional file 2. Fig. S2: List of blood cytokines in C57BL/6J female mice treated with vehicle or 2.5, 5, or 10 mg/kg SI-2 twice a day for 7 days.

Additional file 1: Figure S1. Pie chart shows the number of differentially expressed lncRNAs in each category.

Additional file 4: Figure S3. Volcano plot showing the log2 fold change of 517 significantly differentially expressed miRNAs in CRC patients from the TCGA database.